Mark P. Lappe

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Diego, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Kelly D. Deck, as attorney-in-fact for Mark P. Lappe
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Mark P. Lappe

Form 4 holding Chief Executive Officer, Director

Inhibrx Biosciences, Inc.

Security class
Common Stock
Shares / value
705,548
Estimated value
$12,086,037
Report date
16 Sep 2024
Price
$17.13
Ownership
By the Lappe Family Trust
Form 4 holding Chief Executive Officer, Director

Inhibrx Biosciences, Inc.

Security class
Common Stock
Shares / value
165,000
Estimated value
$2,826,450
Report date
12 Sep 2024
Price
$17.13
Ownership
By Lappe Descendants' Trust
Form 4 holding Chief Executive Officer, Director

Inhibrx Biosciences, Inc.

Security class
Common Stock
Shares / value
54,865
Estimated value
$939,837
Report date
12 Sep 2024
Price
$17.13
Ownership
The Mark Paul Lappe Roth IRA
Form 4 holding Chief Executive Officer, Director

Inhibrx, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
30 May 2024
Price
$30.00
Ownership
By the Lappe Family Trust
Form 4 holding Chief Executive Officer, Director

Inhibrx, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
30 May 2024
Price
$30.00
Ownership
By trust
Form 4 holding Chief Executive Officer, Director

Inhibrx, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
30 May 2024
Price
$30.00
Ownership
The Mark Paul Lappe Roth IRA
Form 4 holding Chief Executive Officer, Director

Inhibrx, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
$0
Report date
30 May 2024
Price
$34.12
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

Inhibrx Biosciences, Inc.

Security class
Stock Option (right to buy)
Shares / value
300,000
Estimated value
Report date
30 May 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Mark P. Lappe

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .